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Chemotherapeutic drugs used in the treatment of
acute myeloid leukemias (AMLs) are thought to
induce cancer cell death through the generation of
DNA double-strand breaks. Here, we report that
one of their early effects is the loss of conjugation
of the ubiquitin-like protein SUMO from its targets
via reactive oxygen species (ROS)-dependent inhibi-
tion of the SUMO-conjugating enzymes. Desumoyla-
tion regulates the expression of specific genes, such
as the proapoptotic gene DDIT3, and helps induce
apoptosis in chemosensitive AMLs. In contrast, che-
motherapeutics do not activate the ROS/SUMO axis
in chemoresistant cells. However, pro-oxidants or
inhibition of the SUMOpathway by anacardic acid re-
stores DDIT3 expression and apoptosis in chemore-
sistant cell lines and patient samples, including
leukemic stem cells. Finally, inhibition of the SUMO
pathway decreases tumor growth in mice xeno-
grafted with AML cells. Thus, targeting the ROS/
SUMO axis might constitute a therapeutic strategy
for AML patients resistant to conventional chemo-
therapies.
INTRODUCTION
Acute myeloid leukemias (AMLs) are severe hematological
malignancies induced by the oncogenic transformation of he-
matopoietic stem and myeloid progenitor cells. It leads to bone
marrow failure and related complications, including infections,
anemia, or bleeding. Despite recent progress in the molecular
characterization and prognosis refinement of this disease (Can-
cer Genome Atlas Research Network, 2013), treatments have
not significantly changed during the past 30 years. The standardCinduction chemotherapy relies on a combination of the nucleo-
side analog cytarabine (Ara-C) with an anthracyclin, such as
daunorubicin (DNR) or idarubicin, sometimes in association
with other drugs, such as etoposide (VP16). Although most
patients reach the complete remission after initial chemothera-
peutic treatment, relapses are frequent, and the global prognosis
remains poor with an overall survival of 40% in young patients
and much less in old ones (Estey, 2012). Relapses are largely
due to the persistence of leukemic stem cells (LSCs), which
are refractory to chemotherapeutic drug-induced cell death
(Vergez et al., 2011).
Generally, the mechanisms of action of the chemotherapeutic
drugs used for AMLs treatment rely on the inhibition of DNA syn-
thesis and the induction of DNA double-strand breaks in highly
replicating cancer cells, which in fine lead to their apoptosis.
However, these drugs can induce cell death by other mecha-
nisms. In particular, reactive oxygen species (ROS) have been
known as critical mediators of genotoxics-induced cell death
for long (Mate´s et al., 2012). They are also responsible for certain
side effects of chemotherapeutic drugs, such as anthracyclin
cardiotoxicity (Gewirtz, 1999; Hole et al., 2011). However, their
cellular effectors have not been clearly identified (Mate´s et al.,
2012).
SUMO is a family of three related ubiquitin-like peptidic post-
translational modifiers, SUMO-1, -2, or -3, the latter two being
almost identical (referred to as SUMO-2/3). SUMO is conjugated
to ε-amino groups of lysines of numerous target proteins by a
heterodimeric SUMO-activating E1 enzyme (AOS1/UBA2), a
SUMO-conjugating E2 enzyme UBC9 (encoded by UBE2I) and
various E3 factors facilitating its transfer from the E2 onto sub-
strates. Most sumoylated proteins go through constant cycles
of conjugation/deconjugation due to various desumoylases.
Sumoylation changes substrate protein properties, in particular
by favoring the recruitment of SUMO-binding partners (Flotho
andMelchior, 2013). Sumoylation is sensitive to various stresses
that regulate the activity of the SUMO pathway’s enzymes. In
particular, ROS can inactivate SUMO conjugation by inducingell Reports 7, 1815–1823, June 26, 2014 ª2014 The Authors 1815
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Figure 1. Chemotherapeutic Drugs Induce
Desumoylation in AML Cells
(A) HL60 cells were treated with Ara-C, VP16, or
DNR for 7 hr and immunoblotted for SUMO-1,
SUMO-2, and active caspase-3 (B).
(B and C) HL60 cells were treated with 1 mM DNR
(B) or 2 mM Ara-C (C) for the indicated times and
immunoblotted for SUMO-1, SUMO-2, or active
CASPASE-3.
(D) Primary AML cells were treated in vitro with
VP16 (10 mM), Ara-C (2 mM), or DNR (1 mM) for 24 hr
and immunoblotted for SUMO-1, SUMO-2, active-
caspase-3, and GAPDH.the formation of a reversible disulfide bridge between UBA2 and
UBC9 catalytic cysteines (Bossis and Melchior, 2006). This dis-
rupts the sumoylation/desumoylation cycle, resulting in protein
desumoylation. Such global shifts in the cell sumoylome are
thought to play critical roles in the cellular response to these
stresses (Tempe´ et al., 2008). Although sumoylation controls
many cellular functions, one well-characterized role is the regu-
lation of transcription via the modification of histones, transcrip-
tion factors and cofactors, chromatin-modifying enzymes, and
basal transcription machinery (Raman et al., 2013). Finally,
deregulation of the SUMO pathway has been found in various
cancers (Bettermann et al., 2012) and is generally associated
with an adverse outcome (Driscoll et al., 2010). Moreover, recent
evidence suggests that targeting sumoylation could be benefi-
cial for cancer treatment. In particular, inhibition of sumoylation
preferentially induces death of Myc-overexpressing cancer cells
(Kessler et al., 2012).
Here, we address the role of the SUMO pathway in AMLs
apoptotic response to chemotherapeutic drugs. We show that
the genotoxics currently used in the clinic induce rapid ROS-
dependent protein desumoylation, which participates both in
transcriptome alteration and apoptosis of chemosensitive AML
cells. Failure to activate this ROS/SUMO axis is associated
with AMLs chemoresistance. However, its induction by different
means is sufficient to induce death of chemoresistant AML cell
lines, as well as that of AML patient cells, including their leukemic
stem cells. Furthermore, inhibition of the SUMO pathway re-
duces AML cell growth in xenografted mice. Overall, our work
identifies the ROS/SUMO axis as a novel player in chemothera-
peutic drugs-induced apoptosis and a potential target to over-
come chemoresistance in AMLs.
RESULTS
Chemotherapeutic Drugs Induce Massive
Desumoylation in Chemosensitive AMLs
A chemosensitive AML model cell line, HL60 (Quillet-Mary et al.,
1996), was treated with Ara-C, DNR, and VP16 at doses consis-1816 Cell Reports 7, 1815–1823, June 26, 2014 ª2014 The Authorstent with plasma concentrations in
treated AML patients (Gewirtz, 1999;
Krogh-Madsen et al., 2010). This induced
a dose-dependent decrease in SUMO-1
and SUMO-2/3 (Figure 1A) conjugate
levels and the appearance of freeSUMO, which did not result from increased SUMO-1 or -2
gene transcription (Figure S1). This suggested that these chemo-
therapeutic drugs induced SUMO deconjugation from its target
proteins. Desumoylation rapidly began after drug addition, as
indicated by the increase in the free SUMO pool already after
1 hr of treatment. Desumoylation onset preceded mitochondrial
membrane potential loss (Figure S2), caspase-3 activation, and a
more global disappearance of SUMO conjugates visible after
3–4 hr (Figures 1B and 1C). Importantly, primary chemosensitive
AML cells (Figure 1D), as well as two other chemosensitive AML
cell lines (U937 and THP1) (Figure S3), also showed massive
drug-induced decrease in SUMO conjugates correlating with
caspase-3 activation. These data indicated that one of the early
effects of chemotherapeutic drugs currently used to treat AMLs
is the induction of protein desumoylation.
Chemotherapeutic Drug-Induced Desumoylation
Regulates Gene Expression and Apoptosis
Considering the acknowledged role of sumoylation in the control
of gene expression, we askedwhether desumoylation could alter
specific transcriptional program. To this aim, we profiled and
compared the transcriptome of HL60 cells treated with anacar-
dic acid, a natural inhibitor of the SUMO E1 enzyme (Fukuda
et al., 2009), with that of mock (DMSO) -treated cells. We found
318 significant differentially expressed (SDE) genes (fold change
over 2-fold), 200 being upregulated (71 more than 3-fold), and
118 downregulated (ten more than 3-fold) (Table S1). Gene
ontology analyses revealed that upregulated genes are involved
in cellular processes such as the response to endoplasmic retic-
ulum (ER) stress, transcription control, nucleosome assembly,
cell-cycle arrest, and apoptosis (Figure 2A). No specific process
was significantly enriched (p < 0.01) for the downregulated genes
(data not shown). We confirmed the transcriptional activation of
six of the most induced genes by RT-qPCR and showed that the
expression of these genes was also strongly activated by Ara-C
(Figure 2B), suggesting that chemotherapeutic drug-induced de-
sumoylation is involved in their induction. We further studied the
DNA Damage-Induced Transcript 3 (DDIT3) gene, as it encodes
the CHOP10/GADD153 protein, an activator of apoptosis
involved in the ER stress response. CHOP10 has also been impli-
cated in the apoptotic response of AML cells to chemothera-
peutic drugs (Eymin et al., 1997). While DDIT3 mRNA levels
increased upon DNR and Ara-C treatment of HL60 cells,
SUMO conjugates rapidly decreased in the gene proximal pro-
moter region (Figures 2C and 2D). Sumoylation of promoter-
bound proteins is principally associated with transcriptional
repression (Cuben˜as-Potts and Matunis, 2013) or limitation of
transcriptional activity (Rosonina et al., 2010), including in the
case of the DDIT3 gene (Tempe´ et al., 2014). Consistent with
this idea, counteracting protein desumoylation by overexpress-
ing SUMO-2 significantly reduced DDIT3 induction by Ara-C
(Figure 2E). Moreover, overexpression of SUMO-2 delayed
Ara-C-induced apoptosis (Figure 2F). Thus, in chemosensitive
AML cells, drug-induced desumoylation stimulates genes,
such as DDIT3, and facilitates the induction of apoptosis.
ROS Are Involved in Chemotherapeutic Drug-Induced
Protein Desumoylation in AMLs
Chemotherapeutic drugs induce the production of ROS (Ge-
wirtz, 1999). As shown in Figure 3A, Ara-C, DNR, and VP-16
led to the formation of the ROS-induced disulfide crosslink be-
tween UBA2 and UBC9 catalytic cysteines (Bossis andMelchior,
2006). Importantly, this correlated with a strong decrease in the
level of the UBC9SUMO thioester adduct, the active form of
UBC9. Using a mouse retroviral model of AML (Michaud et al.,
2010; Moreau-Gachelin, 2006), we showed that the treatment
of leukemic animals with Ara-C and, to a lesser extend with
DNR, also induced UBC9-UBA2 crosslink in vivo in tumor cells
(Figure 3B). Inhibition of NADPH oxidases (NOX), a major source
of ROS in cancer cells (Block and Gorin, 2012), by diphenyle-
neiodonium (DPI) prevented both DNR- and VP16-induced loss
of SUMO conjugates, UBC9-UBA2 crosslinking and apoptosis
(Figure 3C). Finally, treatments of AML patient cells also led to
UBC9-UBA2 crosslinking, the levels of which correlated with
cell sensitivity to the different drugs in vitro (Figures 3D and
3E). These data suggest that chemotherapeutic drug-induced
protein desumoylation in AMLs is a consequence of ROS
production.
The ROS/SUMO Axis Is Not Activated by
Chemotherapeutic Drugs in Chemoresistant AMLs
We next asked whether chemoresistance could be associated
with impaired activation of the ROS/SUMO axis. In contrast to
the chemosensitive U937 and HL60 cells, which exhibit a strong
desumoylation upon DNR, Ara-C, and VP16 treatment, the che-
moresistant AML cell lines TF1 and KG1a (Quillet-Mary et al.,
1996) were resistant to drug-induced desumoylation. This corre-
lated with the absence of ROS-dependent crosslinking of UBA2
to UBC9 (Figures 4A and 4B). We therefore tested whether che-
moresistant AML cells were intrinsically resistant to ROS-depen-
dent protein desumoylation and whether forced activation of the
ROS/SUMO axis could lead to their death. First, TF1 or KG1a
cells were treated with increasing doses of glucose oxidase,
which causes sustained production of ROS from the degradation
of extracellular glucose. This led to UBC9-UBA2 crosslinking
and protein desumoylation (Figures 4C and S4), which correlatedCwith strong induction of DDIT3 mRNA and massive cell death
(Figures 4D and S4). Next, we derived TF1 clones expressing
inducible control- or SUMO-1/2/3 miRNAs. SUMO-1/2/3 RNA
interferencewas sufficient to inducemassive death of these che-
moresistant cells (Figure 4E). Thus, the ROS/SUMO axis is inac-
tive in AML cells that are resistant to chemotherapy-induced
apoptosis. However, its reactivation restores a cell death pro-
gram in these cells.
Inhibition of the SUMO Pathway Targets
Chemoresistant AML Cells In Vitro and In Vivo
Finally, we tested the effect of pharmacological inhibition of pro-
tein sumoylation on AML cells using anacardic acid. It decreased
the amount of SUMO conjugates in chemoresistant TF1 cells
(Figure 5A, left panel), activated caspase 3 (Figure 5A, right
panel) and induced DDIT3 mRNA (Figure 5B), whereas Ara-C
had no effect. Next, we measured anacardic acid IC50 in chemo-
sensitive (HL60, U937) and chemoresistant (TF1, KG1a) cells. All
were sensitive to comparable concentrations of the drug (Fig-
ure 5C). Importantly, anacardic acid had significantly lower effect
on peripheral bloodmononuclear cells (PBMCs) andCD4+ T lym-
phocytes from healthy volunteers, as well as on proliferating
mouse embryonic fibroblasts (MEFs) than on AML cells (Fig-
ure 4C). Similar to AML cell lines, patient samples showed vari-
able sensitivity to Ara-C (IC50 ranging from 2 to >500 mM), but
their IC50 for anacardic acid was relatively homogeneous with
a median concentration of 42 mM (Figure 5D). For seven of the
patient samples, we compared the IC50 of LSCs (CD34
+
CD38low/CD123+) to the bulk of leukemic cells. Although glob-
ally less sensitive to Ara-C-induced cell death, LSCs showed
similar sensitivity toward anacardic acid than the bulk of
leukemic cells (Figure 5E). Interestingly, anacardic acid led to a
strong activation of DDIT3 mRNA in two primary patient sam-
ples, either chemosensitive (Figure 5F, left panel, IC50 = 10 mM
for Ara-C) or chemoresistant (Figure 5F, right panel, IC50 =
250 mM for Ara-C), whereas Ara-C induced DDIT3 expression
only in the chemosensitive sample. Finally, nude mice xeno-
grafted with chemoresistant KG1a cells and peritumorally
treated with anacardic acid showed a significant delay in tumor
growth (Figures 5G–5I). Anacardic acid did however not alter
general biological parameters in the treated mice, as assayed
by weight control or blood cell counting (Figure S5). These
data suggest that targeting sumoylation might overcome che-
moresistance in AMLs.
DISCUSSION
Although targeted therapies have strongly improved the treat-
ment of a subset of cancer patients, the classical chemothera-
peutic drugs remain the standard therapy in most cancers.
This is especially true for acute myeloid leukemia patients whose
front-line treatment is generally a combination of an anthracyclin
and the nucleoside analog Ara-C. Here, we show that a role of
these drugs is the inhibition of the SUMO pathway. They induce
a progressive loss of conjugation of SUMO to its targets, gene
promoter-bound proteins being among the most rapidly
affected. Recent studies reveal that SUMO can be considered
as an integral component of chromatin and regulates specificell Reports 7, 1815–1823, June 26, 2014 ª2014 The Authors 1817
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Figure 2. Desumoylation Regulates Specific Transcriptional Programs and Participates in the Induction of Apoptosis
(A) Top categories identified by gene ontologies of genes upregulated (more than 2-fold) in HL60 cells treated with anacardic acid (100 mM) for 5 hr compared to
mock (DMSO) -treated cells.
(B) HL60 cells were treated with 100 mM anacardic acid (5 hr) or 2 mM Ara-C (3 hr) or control vehicle and mRNA for the indicated genes were monitored by RT-
qPCR (n = 3).
(legend continued on next page)
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Figure 3. Chemotherapeutic Drug-Induced
ROS Inhibit SUMO-E1 and E2 Enzymes
(A) HL60 cells were treated with Ara-C, VP16, or
DNR for 7 hr or H2O2 (15 min), lysed in a nonre-
ducing sample buffer and immunoblotted for
UBC9 and UBA2.
(B) Leukemic FrCasE-infected mice were treated
with DNR (10 mg/kg) or Ara-C (50 mg/kg) every
2 days for 2 weeks and sacrificed 4 hr after the
last injection. Spleen extracts (in nonreducing or
reducing conditions) were immunoblotted for
UBC9.
(C) HL60 and U937 cells were treated with DNR
(1 mM) or VP16 (10 mM) for 7 hr ± DPI (10 mM) and
immunoblotted for SUMO-1, UBC9 (nonreducing
gel), or active caspase-3.
(D) Primary leukemic cells (same patient as in
Figure 1D) were treated in vitro with VP16 (10 mM),
Ara-C (2 mM), or DNR (1 mM) for 24 hr and
immunoblotted for UBC9 (nonreducing gel) and
active-CASPASE-3.
(E) Same as (C) with three other patient samples
immunoblotted for UBC9 (nonreducing gel),
SUMO-1, and GAPDH. Viability was assessed and
compared to mock-treated cells.transcriptional programs (Neyret-Kahn et al., 2013). Consistent
with this, our gene expression data suggest that desumoylation
triggers the expression of genes associated with the ER stress,
apoptosis induction, nucleosome remodeling, and cell-cycle
arrest. Considering the various roles of sumoylation, in partic-
ular, in the control of genome integrity (Jackson and Durocher,
2013), we do not exclude that drug-induced hyposumoylation
might also have other consequences, including impairment of
genotoxics-induced DNA damage repair. However, our data
suggest that one of its important roles is to regulate the expres-
sion of specific genes involved in AML cell response to chemo-
therapeutic drugs.
ROS can no longer be considered solely as toxic molecules
causing random damages to biomolecules. They are also essen-
tial second messengers regulating numerous signaling path-
ways (Paulsen and Carroll, 2010). Consistent with this, we
show here that they are responsible for drug-induced inhibition(C and D) HL60 cells were treated with 1 mMDNR (C) or 2 mMAra-C (D) for the indicated times before analysis
Ara-C). SUMO-2/3 on the DDIT3 promoter was assayed by ChIP (right panels) and normalized to DNA input. S
DNR, n = 3 for Ara-C).
(E) HL60 cells infected with pMIG or pMIG-SUMO-2 lentiviral vectors were treated with Ara-C (2 mM) for 4 h
(F) The same cells as in (E) were treated with 2 mM Ara-C for the indicated times and flow cytometry-analyz
Results are expressed as means ± SD.
Cell Reports 7, 1815–182of the SUMO pathway in chemosensitive
AML cell lines and patient samples. This
is due to their ability to promote the for-
mation of a disulfide-bond between the
catalytic cysteines of the SUMO E1 and
E2 enzymes (Bossis and Melchior,
2006). Although only a fraction of both
E1 and E2 are crosslinked upon chemo-
therapeutic drug treatment, this inactiva-tion involves the active fraction of these enzymes. Given the
fact that desumoylases are not inhibited by these ROS concen-
trations (Feligioni and Nistico`, 2013), this explains the massive
protein desumoylation we observed. Importantly, the inhibition
of ROS production with an NADPH oxidase inhibitor strongly
dampened drug-induced protein desumoylation and delayed
entry into apoptosis. This confirms the role of ROS production
in drug-induced death of chemosensitive AML cells. An impor-
tant issue is whether chemotherapeutic drugs can also induce
the ROS/SUMO axis in other types of cancer. Our data (data
not shown) suggest that this might not always be the case
because, even though we could detect the UBC9-UBA2 cross-
link in an ALL (acute lymphocytic leukemia) cell line treated
with DNR or Ara-C, we could not in epithelial cancer cell lines,
such as MCF-7, HEK293, or HeLa. This might reflect differences
in antioxidant or ROS production capacities between cancer
types.of DDIT3mRNA (left panels, n = 4 for DNR, n = 6 for
UMO level in nontreated cells was set to 1 (n = 7 for
r. DDIT3 mRNA was RT-qPCR assayed (n = 7).
ed for active-CASPASE-3 (n = 3).
3, June 26, 2014 ª2014 The Authors 1819
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Figure 4. Reactivation of the ROS/SUMO
Axis Restores Chemoresistant AML Cells
Death
(A) U937 and TF1 cells were treated with Ara-C,
VP16 or DNR for 7 hr and immunoblotted for
SUMO-1 or UBC9 (nonreducing gel).
(B) HL60 and KG1a cells were treated with Ara-C
(2 mM), DNR (1 mM), or VP16 (10 mM) for 7 hr and
processed as in (A).
(C) TF1 cells were treated with glucose oxidase
(G/O) for 6 hr and immunoblotted for SUMO-2 or
UBC9 (nonreducing gel).
(D) TF1 cells were treated with Ara-C (2 mM) or
glucose oxidase (10 mU/ml). DDIT3 mRNA was
analyzed after 6 hr of treatment usingmock-treated
cells as a reference (left panel, n = 3), and cell
viability was assessed at 24 hr (right panel, n = 3).
(E) TF1 clones expressing a control or SUMO-1/2/3
miRNAs under the control of 4-OHT-inducible
promoter were treated with 4OHT (20 nM) for
5 days and viability was assessed by MTS (n = 3).
Results are expressed as means ± SD.Chemotherapeutic drugs do not activate the ROS/SUMO axis
in chemoresistant AML cells. The absence of ROS-induced
UBC9-UBA2 disulfide-crosslinking upon treatment suggests
that this might be due to lower ROS production and/or higher
antioxidant capacity of chemoresistant AML cells. Along this
line, LSCs, which are highly resistant to chemotherapeutic drugs
and thought to be responsible for relapses, produce less ROS
than the bulk of leukemic cells (Lagadinou et al., 2013). At least
two lines of evidence suggest that increasing ROS concentration
could be of therapeutic value for treating AMLs: (1) the inhibition
of antioxidant systems induces primitive CD34+ AML cell death
(Pei et al., 2013) and (2) pro-oxidants induce the regression of
acute promyelocytic leukemia (a subtype of AMLs characterized
by a chromosome translocation fusing the PML and RARA
genes) in mouse models (Jeanne et al., 2010). However, the clin-
ical usefulness of pro-oxidant therapies might be limited by their
toxicity (Hole et al., 2011; Mate´s et al., 2012). An alternative strat-
egy to activate the ROS/SUMO axis in chemoresistant cells may
therefore consist of targeting the SUMO pathway. In support of
this idea, anacardic acid, a natural molecule of the Chinese phar-
macopeia known to trigger apoptosis of various cancer cell lines
in vitro (Tan et al., 2012) induced death of chemoresistant AML1820 Cell Reports 7, 1815–1823, June 26, 2014 ª2014 The Authorscell lines in vitro and in vivo as well as
that of patient leukemic cells, including
LSCs. Moreover, the absence of overt
toxicity of anacardic acid on nontrans-
formed cells and in living mice (except
local sensitization when injected subcuta-
neously; data not shown) suggests that
inhibiting the SUMO pathway may have
less severe side effects than pro-oxidant
therapies. Chemical engineering of ana-
cardic acid to improve its solubility and
bioavailability or developing novel SUMO
pathway inhibitors might therefore offer
an avenue to improve the outcome ofAMLs patients by targeting leukemic cells, including LSCs resis-
tant to conventional chemotherapies.
EXPERIMENTAL PROCEDURES
Pharmacological Inhibitors, Reagents, and Antibodies
Cytosine-b-D-arabinofuranoside (Ara-C), daunorubicin-hydrochloride (DNR),
etoposide (VP-16), glucose-oxidase, and hydrogene-peroxide were from
Sigma. Anacardic acid from Merck Millipore. SUMO-1 (21C7) and SUMO-2
(8A2) hybridomas were from the Developmental Studies Hybridoma Bank.
Goat anti-SUMO-2 (used for chromatin immunoprecipitation [ChIP]) and
anti-UBA2 were previously described (Bossis and Melchior, 2006). Anti-
UBC9 (sc-10759) and GAPDH (sc-25778) were from Santa Cruz Biotechnol-
ogies; anti-cleaved CASPASE-3 (D175) were from Cell Signaling Technology.
Antibodies and gating strategies used to phenotype patient samples were
described previously (Vergez et al., 2011).
Cell Lines and Clinical Samples
U937, HL60, THP1, KG1a, and TF1 cells (DSMZ, Germany) were cultured in
RPMI or Iscove modifier Dulbecco’s medium (IMDM) (for KG1a) with 10% fetal
bovine serum (FBS). TF1 were cultured with addition of 2 ng/ml GM-CSF
(PeproTech). Mouse embryonic fibroblasts were a kind gift from M. Bialic
and were cultured in DMEMwith 10% FBS. For treatments, cells were seeded
at 0.3 3 106 cells/ml the day before the experiment, and fresh medium was
added together with the drugs. PBMC and CD4+ lymphocytes were purified
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Figure 5. Inhibition of Sumoylation with Anacardic Acid Induces Chemoresistant Cells Death and Reduces Tumor Growth In Vivo
(A) TF1 cells were treated with anacardic acid for 8 hr and immunoblotted for SUMO-2 or active-CASPASE-3.
(B) TF1 cells were treated with Ara-C (2 mM) or anacardic acid (Anac, 100 mM) for 4 hr before DDIT3 mRNA RT-qPCR assay (n = 3).
(C) HL60, U937, TF1, KG1a, PBMC, CD4+ T lymphocytes, and MEF cells were treated with increasing doses of anacardic acid or Ara-C for 24 hr before viability
assay using MTS (n = 3).
(D and E) Primary AML cells IC50 of anacardic acid (n = 23) and Ara-C (n = 17) wasmeasured on the bulk of leukemic cells (CD45/SSC gating) at 24 hr (D). For some
of the samples (n = 7), IC50 of the bulk of leukemic cells was compared to that of LSCs (CD34
+CD38low/CD123+) (E). IC50 >500 mM could not be calculated
precisely and were set to 500 mM. The same color is used for data coming from the same patient sample.
(F) AML cells were treated with 50 mM anacardic acid or 10 mM Ara-C for 24 hr before DDIT3 mRNA RT-qPCR assay.
(G–I) Mice xenografted with KG1a were treated with anacardic acid or the vehicle (DMSO), and tumor growth was measured for 17 days (G). Mice were then
sacrificed and tumor volume (H) as well as tumor weight (I) were measured. Results are expressed as means ± SD.
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from peripheral blood. Bonemarrow aspirates containing leukemic blasts from
patients diagnosed with AMLs were obtained as previously described (Vergez
et al., 2011) after informed consent and stored at the HIMIP collection (DC-
2008-307-collection1). A transfer agreement was obtained (AC-2008-129)
after approbation by the ‘‘Comite´ de Protection des Personnes Sud-Ouest
et Outremer II’’ (Ethical Committee). For some experiments, fresh leukemic
blasts recovered at diagnosis were immediately treated with the drugs or in-
hibitors. In most cases, frozen cells were thawed in IMDM with 20% FBS
and immediately processed.
Lentiviral and Retroviral Infections
Retroviral constructs expressing SUMO-2 were constructed by inserting His-
tagged human SUMO-2 cDNA into the pMIG retroviral vector. The 4-hydroxy-
tamoxifen(4-OHT)-inducible control and SUMO-1/2/3 miRNA (miR-SUMO-1/
2/3) lentivirus were a kind gift from Dr. W. Paschen (Yang et al., 2013). Viruses
were produced in HEK293T cells by transfection using Lipofectamine-2000
(Invitrogen) of viral constructs together with gag-pol (lentiviral or retroviral)
and env (VSVG) expression vectors. Viral supernatants were collected 48 hr
after transfection, 0.45 mM filtered and used to infect AML cell lines. For
pMIG-infected cells, only GFP-positive cells were considered in the flow
cytometry analysis. For the miR-control and miR-SUMO-1/2/3, clones resis-
tant to hygromycin and puromycine were selected and tested for inhibition
of SUMO-1/2/3 expression.
Microarray-Based Whole-Transcript Expression Analysis and
Profiling
Total RNA was extracted using the GenEluteMammalian Total RNA kit (Sigma)
and treated with DNase I according to the manufacturer’s specifications. For
each condition, three independent batches of RNA were prepared and con-
trolled for purity and integrity using the Agilent 2100 Bioanalyzer with RNA
6000 Nano LabChip kits (Agilent Technologies). Only RNA with no sign of
contamination or degradation (RIN >9) were further processed to generate
amplified and biotinylated sense-strand cDNA targets using the GeneChip
WT PLUS Reagent kit from Affymetrix according to the manufacturer’s specifi-
cations. After fragmentation, cDNA targets were used to probe Affymetrix
GeneChip Human Gene 2.0 ST arrays, which were then washed, stained, and
scanned according to Affymetrix instructions (usermanual P/N 702731 Rev. 3).
Microarrays, Data Analysis, and Gene Ontology
CEL files generated after array scanning were imported into the Partek Geno-
mics Suite 6.6 (Partek) for preprocessing consisting of estimating transcript
cluster expression levels from raw probe signal intensities. Analyses were per-
formed using default Partek settings. Resulting expression data were then
imported into R (http://www.R-project.org/) for further analysis. First nonspe-
cific filtering was applied to remove transcript clusters with no specified chro-
mosome location. Then, box plots, density plots, relative log expressions
(RLEs), and sample pairwise correlations were generated to assess the quality
of the data. They revealed no outlier within the series of hybridizations. Prin-
cipal component analysis (PCA) was also applied to the data set. The first
two components of the PCA were able to separate samples according to
the treatment. Thus, the treatment was considered as the unique source of
variability. Finally, the LIMMA package (Smyth, 2005) (R/Bioconductor) was
used to detect differentially expressed genes (DEGs) between treated and
nontreated samples. A linear model with treatment as unique factor was fitted
to the data before applying eBayes function to calculate the significance of the
difference in gene expression between the two groups. p values were adjusted
by Benjamin and Hochberg’s false discovery rate (FDR) (Benjamini and Hoch-
berg, 1995) and genes with FDR less than 0.05 and absolute linear fold change
(FC) greater or equal to 2 were considered as DEG. Gene Ontologies associ-
ated with the DEG were obtained with BINGO (Maere et al., 2005).
Chromatin Immunoprecipitation and RT-qPCR
ChIPswere performed as previously described (Tempe´ et al., 2014). The immu-
noprecipitated DNA and inputs taken from samples before immunoprecipita-
tion were analyzed using the Roche LightCycler 480 with primers specific for
the proximal promoter DDIT3 gene (forward: 50-atgactcacccacctcctccgtg-30;
reverse: 50-ccccgtcgctccctctcgcta-30). Total RNA was purified using the1822 Cell Reports 7, 1815–1823, June 26, 2014 ª2014 The AuthorsGenElute Mammalian Total RNA kit (Sigma). After DNase I treatment, 1 mg of
total RNA was used for cDNA synthesis with the Maxima First Strand cDNA
(Thermo Scientific) and used for qPCR with primers specific for the DDIT3
mRNA (forward: 50-gtcacaagcacctcccagagcc-30; reverse: 50-tctgtttccgtttc
ctggttctcc-30 ). Data were normalized to GAPDH or TBP mRNA levels.
Caspase 3 Activity Assay
Cells were fixed with 4% paraformaldehyde for 20 min and permeabilized with
digitonin-containing buffer (eBioscience) for 15 min before addition of anti-
cleaved CASPASE-3 antibody. After 2 hr, cells were washed and incubated
with an anti-rabbit Alexa 647 antibody (Molecular Probes) for 1 hr, washed,
and analyzed by flow cytometry.
Viability Assays
Cells were treated with increasing doses of drugs. After 24 hr, MTS assay
(Promega) was used to assess the percentage of metabolically active cells
according to manufacturer protocol. For primary AMLs, cells were stained
with CD45-V450, CD34-PE-Cy7, CD38-APC, CD123-PE, AnnexinV-FITC, and
7-AAD as previously described (Vergez et al., 2011), and viability of the bulk of
leukemic cells (CD45/SSC gating) or of LSCs (CD34+CD38low/CD123+) was
determined by flow cytometry as the percentage of AnnexinV/7-AAD cells
within each population. IC50 were calculatedwith Prism 4 software (GraphPad).
In Vivo Treatment with Chemotherapeutic Drugs
The mouse AML model used in this study was the erythroleukemia induced by
the FrCasE Murine Leukemia Virus (Michaud et al., 2010). Eight-day-old
129S7/SvEvBrdBkl-Hprtb-m2 mice (H-2Db haplotype) were infected intraperi-
toneally with 100 ml of a FrCasE virus suspension containing 5 3 105 ffu/ml.
Mice were examined at regular intervals for clinical signs of erythroleukemia
(spleen swelling and reduction in hematocrits). Two-month-old leukemic
mice were subjected to intraperitoneal administration of DNR (10 mg/kg) or
Ara-C (50 mg/kg) every 2 days for 2 weeks and euthanized 4 hr after the
last injection. Their spleens, as well as those of mock-treated leukemic mice
of the same age, were lysed in 20 mM Na2HPO4 pH 7.4, 150 mM NaCl, 1%
Triton X-100, 0.5% Na-deoxycholate, 0.1% SDS, 5 mM EDTA, 5 mM EGTA,
1 mg/ml of a aprotinin/pepstatin/leupeptin mix, 10 mM N-Ethyl-Maleimide
using a Dounce homogeneizer. Homogenates were cleared by centrifugation
(20,0003 g for 10 min), and supernatants were used for immunoblotting anal-
ysis after protein concentration normalization.
Tumor Xenografts
Xenograft tumors were generated by injecting 23 106 KG1a cells (in 100 ml of
PBS) subcutaneously on both flanks of NU/NU Nude mice (adult male and
females, 25 g, Charles River Laboratories). Mice were given peritumoral injec-
tions of anacardic acid (2mg/kg/day in 30 ml) or vehicle (DMSO). Tumor dimen-
sions were measured with a caliper and volumes calculated using the formula:
v = p/6xAxB2, where A is the larger diameter and B is the smaller diameter. At
the end of the experiment, tumors were dissected, measured and weighed.
Animal experiments were approved by the Ethical Committee from the
UMS006 (approval number 13-U1037-JES-08).
Statistical Analyses
Results are expressed as means ± SD. Statistical analyses were performed by
Student’s t test with Prism 4 software. Differences were considered as signif-
icant for p values of <0.05. *p < 0.05; **p < 0.01; ***p < 0.001.
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